Focuses on developing therapies for adrenal diseases and disorders.
Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company based in Ponte Vedra, Florida, specializing in the advancement of innovative therapies. At the core of its research efforts is Tecarfarin, a novel treatment designed as an orphan drug for preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation.
Founded in 2022, Cadrenal Therapeutics is committed to addressing critical medical needs through its focused development programs. Tecarfarin represents a significant advancement in therapeutic options for patients at high risk of cardiac-origin thromboembolic events, leveraging the company's dedication to improving patient outcomes and quality of life.
With a strategic headquarters in Ponte Vedra, Cadrenal Therapeutics continues to push the boundaries of biopharmaceutical innovation. The company's mission is underscored by its relentless pursuit of effective treatments that meet the urgent medical needs of patients facing complex cardiovascular conditions associated with end-stage renal disease and atrial fibrillation.